Pharmaceutical quality of inhalation and nasal products - Scientific guideline
Submitted by Anonymous (not verified) on 27 January 2026 - 12:15
Pharmaceutical quality of inhalation and nasal products - Scientific guideline
PSUSA/00002303/202505
Submitted by Anonymous (not verified) on 27 January 2026 - 10:54
PSUSA/00002303/202505
PSUSA/00002037/202506
Submitted by Anonymous (not verified) on 27 January 2026 - 10:48
PSUSA/00002037/202506
PSUSA/00001859/202506
Submitted by Anonymous (not verified) on 27 January 2026 - 10:39
PSUSA/00001859/202506
Minutes of the CAT meeting 5-7 November 2025
Submitted by Anonymous (not verified) on 27 January 2026 - 10:32
Minutes of the CAT meeting 5-7 November 2025
Human medicines European public assessment report (EPAR): Mvasi, bevacizumab, Date of authorisation: 15/01/2018, Revision: 18, Status: Authorised
Submitted by Anonymous (not verified) on 27 January 2026 - 10:30
Human medicines European public assessment report (EPAR): Mvasi, bevacizumab, Date of authorisation: 15/01/2018, Revision: 18, Status: Authorised
PSUSA/00002131/202503
Submitted by Anonymous (not verified) on 27 January 2026 - 10:28
PSUSA/00002131/202503
Q&A clinic on Product Management Service (PMS) Product User Interface (PUI) and Application Programming Interface (API) - January 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 13 January 2026, 15:00 (CET) to 13 January 2026, 16
Submitted by Anonymous (not verified) on 27 January 2026 - 9:40
Q&A clinic on Product Management Service (PMS) Product User Interface (PUI) and Application Programming Interface (API) - January 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 13 January 2026, 15:00 (CET) to 13 January 2026, 16:00 (CET)
PSUSA/00001500/202504
Submitted by Anonymous (not verified) on 27 January 2026 - 9:30
PSUSA/00001500/202504
PSUSA/00003154/202505
Submitted by Anonymous (not verified) on 27 January 2026 - 9:25
PSUSA/00003154/202505